The DOI matches its Crossref record; 73 of the 74 references it cites were found in a registry or an index.
Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms
Open accessAbstract
Mutations in the microtubule-associated protein tau gene have been linked to neurofibrillary tangle (NFT) formation in several neurodegenerative diseases known as tauopathies; however, no tau mutations occur in Alzheimer's disease, although this disease is also characterized by NFT formation and cell death. Importantly, the mechanism of tau-mediated neuronal death remains elusive. Aged mice expressing nonmutant human tau in the absence of mouse tau (htau mice) developed NFTs and extensive cell death. The mechanism of neuron death was investigated in htau mice, and surprisingly, the presence of tau filaments did not correlate directly with death within individual cells, suggesting that cell death can occur independently of NFT formation. Our observations show that the mechanism of neurodegeneration involved reexpression of cell-cycle proteins and DNA synthesis, indicating that nonmutant tau pathology and neurodegeneration may be linked via abnormal, incomplete cell-cycle reentry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, neuronal loss appears to be independent of tangle formation in some transgenic mouse models (12)(13)(14).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444 · cited 4×
“A number of studies have detected DNA fragmentation, a hallmark of apoptosis, in AD tissue sections using the terminal deoxynucleotide transferase mediated dUTP nick-end labeling (TUNEL) method (Gavrieli et al., 1992; Sgonc and Wick, 1994) to identify 3 -OH ends of broken DNA (Su et al.”
MethodInfluentialAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“However, no mutations have been found in the tau gene in AD, and the relationship between tau pathology, amyloid deposition, and neuronal degeneration is difficult to determine (Hardy and Higgins, 1992; Taylor et al., 2002).”
BackgroundNeurogenesis in the adult human hippocampus
Eriksson, P. S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D. A., & Gage, F. H. (1998) · Nature Medicine · doi:10.1038/3305 · Cited by 6,369 · cited 1×
“…life in specific brain regions, including the subventricular zone of the lateral ventricles and the subgranular zone of the dentate gyrus of the hippocampus (Eriksson et al., 1998; Gould et al., 1998), but it does not normally occur in most regions with large populations of postmitotic neurons.”
BackgroundHengartner, M. O. (2000) · Nature · doi:10.1038/35037710 · Cited by 5,779 · cited 2×
“These pathways are classically grouped based on stereotyped changes in nuclear morphology (Kerr, 1972; Leist and Jaattela, 2001), principally with respect to chromatin condensation, and on the presence or absence of the classic cell executioners: the caspases (for review, see Hengartner, 2000).”
BackgroundThe Ki-67 protein: From the known and the unknown
Scholzen, T. E., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3 · Cited by 4,707
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · cited 1×
“Mutations in the tau gene have been linked to NFT formation in a number of tauopathies in which no -amyloid deposits develop (Hutton et al., 1998; Spillantini et al., 1998; Poorkaj et al., 2001).”
BackgroundSelf-citationWest, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994 · cited 1×
“The optical fractionator (West et al., 1991) was used to obtain quantitative estimates of neuronal loss with age in the htau mice.”
MethodFour deaths and a funeral: from caspases to alternative mechanisms
Leist, M., & Jäättelä, M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35085008 · Cited by 1,600 · cited 2×
“These pathways are classically grouped based on stereotyped changes in nuclear morphology (Kerr, 1972; Leist and Jaattela, 2001), principally with respect to chromatin condensation, and on the presence or absence of the classic cell executioners: the caspases (for review, see Hengartner, 2000).”
BackgroundMethodNeuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“Moreover, there is evidence to suggest that some neurons in AD brain may die without forming NFTs (Gomez-Isla et al., 1997).”
Background
Research works printed but not linked: 5
- 1989, Mol Cell Biol, 9, 1389
- Hof PR (2000) Comparative cytoarchitectonic atlas of the C57BL/6 and 129/Sv mouse brains. Amsterdam: Elsevier.
- 1996, Cancer Res, 56, 816
- 1996, Dementia, 7, 177
- 2003, Prog Cell Cycle Res, 5, 31
Cited by
Sorted by citations
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251
Recovery of learning and memory is associated with chromatin remodelling
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227
Tau in Alzheimer Disease and Related Tauopathies
Iqbal, K., Liu, F., Gong, C., & Grundke, I. (2010) · Current Alzheimer Research · doi:10.2174/156720510793611592 · Cited by 1,163
“[84] showed that in human tau transgenic mice, while there was widespread neurodegeneration, the PHF-containing neurons, however, appeared “healthy” in terms of nuclear morphology, suggesting that the polymerization of hyperphosphorylated tau into fibrils was probably neuroprotective [84].”
BackgroundClassification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
“In transgenic mice overexpressing normal human tau, there are also signs of re-entry: tau accumulation could thus be the cause of the re-entry rather than its consequence [12].”
BackgroundTau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965
“A recent study has shown that tangles continue to form in tau-expressing transgenic mice even after tau expression is switched off, suggesting that soluble, rather than aggregated, tau species are neurotoxic, a view supported by the apparent dissociation between the number of tangles and the extent of neuronal death i…”
ResultRamsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702
“Most recent studies of this model suggest the mechanism of tau-mediated neuronal death may involve the re-expression of cell-cycle proteins, indicating incomplete re-entry of the cell cycle (Andorfer et al., 2005).”
BackgroundRegulation of Tau Pathology by the Microglial Fractalkine Receptor
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R. M., & Lamb, B. T. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.023 · Cited by 639
“, 2003) and neurodegeneration (Andorfer et al., 2005).”
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., & Kayed, R. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-39 · Cited by 633
“Cell death and synaptic lesions occur independently of formation of NFTs in h-tau mice expressing non-mutant human tau [13,14].”
BackgroundMechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
“[11] showed that in human tau transgenic mice, while there was widespread neurodegeneration, the PHF-containing neurons, however, appeared ‘‘healthy’’ in terms of nuclear morphology, suggesting that the polymerization of hyperphosphorylated tau into fibrils was probably neuroprotective [11].”
Involvement of oxidative stress in Alzheimer disease
Nunomura, A., Castellani, R. J., Zhu, X., Moreira, P. I., Perry, G., & Smith, M. A. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000228136.58062.bf · Cited by 611
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
The Unfolded Protein Response Is Activated in Pretangle Neurons in Alzheimer's Disease Hippocampus
Hoozemans, J. J. M., van Haastert, E. S., Nijholt, D. A. T., Rozemuller, A. J. M., Eikelenboom, P., & Scheper, W. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080814 · Cited by 600
Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Brain · doi:10.1093/brain/awv081 · Cited by 595
“3C), suggest that deficiency of microglial CX3CR1 in hTauCx3cr1 / mice induces neurodegeneration, which occurs several months prior to significant neuronal loss demonstrated in the hTau mice (12 months versus 17 months of age) (Andorfer et al., 2005).”
BackgroundInfluentialAnimal models of neurodegenerative diseases
Dawson, T. M., Golde, T. E., & Lagier-Tourenne, C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0236-8 · Cited by 576
“Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.”
Wang, J., Xia, Y., Grundke, I., & Iqbal, K. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129031 · Cited by 547
“[140].”
Lee, S., Varvel, N. H., Konerth, M. E., Xu, G., Cardona, A. E., Ransohoff, R. M., & Lamb, B. T. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100265 · Cited by 522
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506
“In that model as well as in the htau model, region-specific dissociation of neuronal loss and neurofibrillary pathology has been observed (Andorfer et al., 2005; Spires et al., 2006), which suggests toxic effects of early stage pathological tau conformers that cannot easily be detected, analogous to A oligomers.”
Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy
Berger, Z., Roder, H. M., Hanna, A., Carlson, A. M., Rangachari, V., Yue, M., Wszołek, Z. K., Ashe, K. H., Knight, J. A., Dickson, D. W., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0587-07.2007 · Cited by 503
“Neuronal cell death also occurred independently of histologically observed tangles in mice that express all six isoforms of wild-type human tau (Andorfer et al., 2005).”
BackgroundSelf-citationIdentification of oligomers at early stages of tau aggregation in Alzheimer's disease
Lasagna‐Reeves, C. A., Castillo‐Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., & Kayed, R. (2012) · The FASEB Journal · doi:10.1096/fj.11-199851 · Cited by 527
The role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
“Likewise, many of the neurons that accumulate NFT in aged transgenic mice overexpressing normal htau seem "healthy" in terms of nuclear morphology, while a number of dying neurons do not appear to have a significant load of tau filaments [69].”
Alzheimer disease models and human neuropathology: similarities and differences
Duyckaerts, C., Potier, M.-C., & Delatour, B. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0312-8 · Cited by 375
“Cell death in htau mice does not seem to be directly caused by the NFTs but appears to be linked to reexpression of proteins involved in cell-cycle and DNA synthesis [7].”
BackgroundAbnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo
Fulga, T. A., Elson-Schwab, I., Khurana, V., Steinhilb, M. L., Spires, T. L., Hyman, B. T., & Feany, M. B. (2007) · Nature Cell Biology · doi:10.1038/ncb1528 · Cited by 452
“Similarly, although wild-type human tau can show substantial toxicity when expressed in transgenic mic”
BackgroundPractical considerations for choosing a mouse model of Alzheimer’s disease
Jankowsky, J. L., & Zheng, H. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0231-7 · Cited by 449
“Even the htau model overexpressing wild-type human MAPT was initially described with notable neuronal loss, albeit at much later ages (~17 months) [42], and may have since waned with successive generations of breeding (see “Neurofibrillary tangles” section for more detail).”
BackgroundMethodMAPT mutations, tauopathy, and mechanisms of neurodegeneration
Strang, K. H., Golde, T. E., & Giasson, B. I. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0197-x · Cited by 424
Probing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
Microtubule-associated protein tau in development, degeneration and protection of neurons
Wang, J., & Liu, F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.002 · Cited by 405
Spires, T. L., Orne, J. D., SantaCruz, K., Pitstick, R., Carlson, G. A., Ashe, K. H., & Hyman, B. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050840 · Cited by 401
Wang, C., Ward, M. E., Chen, R., Liu, K., Tracy, T. E., Chen, X., Xie, M., Sohn, P. D., Ludwig, C., Meyer-Franke, A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.019 · Cited by 400
“In Drosophila and mouse models, overexpression of wild- type human tau induces neurodegeneration (Wittmann et al., 2001), axonopathy (Spittaels et al., 1999), and extensive cell death (Andorfer et al., 2005) independently of tangle formation.”
BackgroundChanges in the structural complexity of the aged brain
Dickstein, D. L., Kabaso, D., Rocher, A. B., Luebke, J. I., Wearne, S. L., & Hof, P. R. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00289.x · Cited by 460
“These mice exhibit tau pathology in neurons of the neocortex and hippocampus in patterns similar to that occurring in NFTs of human brain and exhibited overt neuronal loss (Andorfer et al., 2003, 2005).”
Self-citationReimagining Alzheimer's Disease—An Age-Based Hypothesis
Herrup, K. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.4521-10.2010 · Cited by 408
“In support of this concept, transgenic mice carrying human tau mutations develop a late-onset neurodegenerative phenotype that includes neuronal loss (Andorfer et al., 2005; Ramsden et al., 2005).”
BackgroundTherapeutic approaches to Alzheimer's disease
Klafki, H., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006) · Brain · doi:10.1093/brain/awl280 · Cited by 362
“Characteristic neuropathological findings include selective neuronal and synaptic losses (Morrison and Hof, 1997), extracellular neuritic plaques containing the b-amyloid peptide (Glenner and Wong, 1984; Masters et al., 1985) and neurofibrillary tangles (NFTs) composed of hyperphosphorylated forms of the tau protein (…”
BackgroundInfluentialOxidative Stress Signaling in Alzheimers Disease
Su, B., Wang, X., Nunomura, A., Moreira, P., Lee, H.-G., Perry, G., Smith, M., & Zhu, X. (2008) · Current Alzheimer Research · doi:10.2174/156720508786898451 · Cited by 344
“Given the fact that neurons with NFT can survive for decades, which is consistent with data in mouse model that NFTs are not involved in neuronal death [120,121], it is tempting to suggest that the formation of neurofibrillary pathology is a further neuronal adaptation to chronic oxidative stress [122].”
Tau pathophysiology in neurodegeneration: a tangled issue
Spires‐Jones, T. L., Stoothoff, W. H., de Calignon, A., Jones, P., & Hyman, B. T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.11.007 · Cited by 321
Characterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease
Patterson, K. R., Remmers, C. L., Fu, Y., Brooker, S. M., Kanaan, N. M., Vana, L., Ward, S., Reyes, J. F., Philibert, K., Glucksman, M., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237974 · Cited by 369
Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau Pathology
Polydoro, M., Acker, C. M., Duff, K., Castillo, P. E., & Davies, P. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1065-09.2009 · Cited by 329
“…mice develop tau pathology in an age-dependent manner We confirmed by immunohistochemistry that all htau animals from the two age groups exhibited an age-dependent tau pathology with very similar features to those present in human AD cases, as previously reported (Andorfer et al., 2003, 2005).”
BackgroundResultInfluentialSelf-citationOxidative stress mediates tau-induced neurodegeneration in Drosophila
Dias-Santagata, D., Fulga, T. A., Duttaroy, A., & Feany, M. B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28769 · Cited by 318
“Interestingly, hallmarks of both apoptotic and necrotic cell death have been recently identified in neurons from transgenic mice expressing nonmutant forms of human tau (53).”
BackgroundMouse models of Alzheimer's disease
Hall, A. M., & Roberson, E. D. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.017 · Cited by 317
Alzheimer disease, the two-hit hypothesis: An update
Zhu, X., Lee, H., Perry, G. L., & Smith, M. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.10.014 · Cited by 299
Naini, S. M. A., & Soussi‐Yanicostas, N. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/151979 · Cited by 330
“These mice also develop neurodegeneration and age-dependent memory loss [72, 73].”
BackgroundBemiller, S. M., McCray, T. J., Allan, K., Formica, S. V., Xu, G., Wilson, G., Kokiko-Cochran, O. N., Crish, S. D., Lasagna-Reeves, C. A., Ransohoff, R. M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0216-6 · Cited by 299
“beginning at approximately 6 months of age [25, 26].”
BackgroundTau phosphorylation and aggregation in Alzheimer's disease pathology
Ávila, J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.02.067 · Cited by 288
“In mice, two approaches have been followed to mimic the AD [55] or FTDP17 (see for example [56,57]) tauopathies.”
BackgroundVingtdeux, V., Davies, P., Dickson, D. W., & Marambaud, P. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0759-x · Cited by 297
“CP13 is commonly used to detect tau pathology in both early (pre-tangles) and more advanced stages of NFT accumulation, whereas PHF1 is a marker for later stage tangles [1, 2].”
Self-citationMolecular Pathogenesis of the Tauopathies
Götz, J., Halliday, G., & Nisbet, R. M. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012936 · Cited by 276
Absalon, S., Kochanek, D. M., Raghavan, V., & Krichevsky, A. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1327-13.2013 · Cited by 302
“Accumulating evidence suggests that CCE in neurons may precede tau and amyloid pathology, and that there is a link between CCE and tau-hyperphosphorylation (Andorfer et al., 2005; Park et al., 2007; Jaworski et al., 2009).”
BackgroundRecent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“2009) and recent evidence that NFTs in experimental models do not directly correlate with neuron loss (Andorfer et al. 2005; SantaCruz et al. 2005) suggests that affected neurons may be able to withhold NFT formation for a long time before they degenerate.”
BackgroundInfluentialImmunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model
Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272
“The htau model (Jackson Laboratories, stock #004808) (Andorfer et al., 2005) was crossed with a model that expresses the PS1 M146L human mutation (Duff et al., 1996).”
BackgroundMethodTau-based therapies in neurodegeneration: opportunities and challenges
Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272
TOR-Mediated Cell-Cycle Activation Causes Neurodegeneration in a Drosophila Tauopathy Model
Khurana, V., Lu, Y., Steinhilb, M. L., Oldham, S., Shulman, J. M., & Feany, M. B. (2006) · Current Biology · doi:10.1016/j.cub.2005.12.042 · Cited by 266
“The issue of causality has previously been unresolved, although important studies have documented aberrant neuronal cell-cycle markers in human tauopathies and, more recently, in a mouse tauopathy model [36].”
Chen, X., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 302
Oxidative stress in alzheimer’s disease: A review on emergent natural polyphenolic therapeutics
Cassidy, L., Fernandez, F., Johnson, J. B., Naiker, M., Owoola, A. G., & Broszczak, D. A. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102294 · Cited by 288
NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation
Amadoro, G., Ciotti, M. T., Costanzi, M., Cestari, V., Calissano, P., & Canu, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511065103 · Cited by 243
Li, H.-L., Wang, H.-H., Liu, S.-J., Deng, Y.-Q., Zhang, Y.-J., Tian, Q., Wang, X.-C., Chen, X., Yang, Y., Zhang, J.-Y., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609303104 · Cited by 225
Tau oligomers and tau toxicity in neurodegenerative disease
Ward, S., Himmelstein, D. S., Lancia, J. K., & Binder, L. I. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120134 · Cited by 244
A decade of modeling Alzheimer's disease in transgenic mice
MCGOWAN, E., ERIKSEN, J., & HUTTON, M. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.03.007 · Cited by 287
Soluble forms of tau are toxic in Alzheimer's disease
Kopeikina, K., Hyman, B., & Spires-Jones, T. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0032-y · Cited by 232
“These and other data argue that synaptic deficits occur in an NFT-independent manner, again making the case that soluble tau serves as the toxic entity [51, 52, 56, 70, 92, 118].”
BackgroundLamin Dysfunction Mediates Neurodegeneration in Tauopathies
Frost, B., Bardai, F. H., & Feany, M. B. (2016) · Current Biology · doi:10.1016/j.cub.2015.11.039 · Cited by 226
“Ectopic expression of cell-cycle markers in postmitotic neurons and their coincidence with tau pathology is a well-described feature of tauopathies [15, 16], and abnormal activation of the cell cycle in neurons can drive apoptosis in tau-transgenic Drosophila [6].”
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice
Corre, S. L., Klafki, H., Plesnila, N., Hübinger, G., Obermeier, A., Sahagún, H., Monse, B., Seneci, P., Lewis, J. M., Eriksen, J. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602913103 · Cited by 232
Lewis, J. M., & Dickson, D. W. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1507-z · Cited by 229
“As a step forward, we suggest that more work should be performed using the Htau model which lacks murine tau [4], but in which both 3R and 4R human tau are spliced and translated, albeit in a different ratio than observed in either humans or mice.”
Wang, Y. P., Biernat, J., Pickhardt, M., Mandelkow�, E., & Mandelkow�, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703676104 · Cited by 216
Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs
Rocher, A. B., Crimins, J. L., Amatrudo, J. M., Kinson, M. S., Todd-Brown, M. A., Lewis, J., & Luebke, J. I. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.029 · Cited by 187
“For example, in mice that overexpress wild-type human tau, extensive neuronal death occurred prior to substantial deposition of aggregated tau and NFTs, and neurons that appeared to be dying exhibited no ultrastructural evidence of fibrillar tau (Andorfer et al., 2005).”
Are tau aggregates toxic or protective in tauopathies?
Cowan, C. M., & Mudher, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00114 · Cited by 215
“showed that, while there was widespread neurodegeneration, the PHF-containing neurons appeared “healthy” in terms of nuclear morphology, suggesting that the polymerized protein was probably neuroprotective (105).”
BackgroundMa, Q., Zuo, X., Yang, F., Ubeda, O. J., Gant, D. J., Alaverdyan, M., Teng, E., Hu, S., Chen, P., Maiti, P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393751 · Cited by 220
“Selective Suppression of Soluble Tau Dimers by Curcumin in Aged hTauMice—AlthoughhTaumice develop age-dependent NFTs with neuronal hyperphosphorylated Tau accumulation by 12 months of age (22, 27), progression of pathophysiology beyond 17 months of age, specifically in relation to synaptic dysfunction or the presence…”
BackgroundMethodPolymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity
Alonso, A. D. C., Li, B., Grundke-Iqbal, I., & Iqbal, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603214103 · Cited by 206
Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193
“Finally, the Ser422 epitope has not been analyzed in other available models similar to THY-‐Tau22 such as the htau model [42] [43].”
Yang, Y., Varvel, N. H., Lamb, B. T., & Herrup, K. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3707-05.2006 · Cited by 175
“In addition, recent studies in transgenic mice producing wild-type human tau but no endogenous mouse tau have documented the formation of neurofibrillary tangles and neuronal cell death associated with altered CCEs (Andorfer et al., 2005).”
Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells
Su, B., Wang, X., Lee, H., Tabaton, M., Perry, G. L., Smith, M. A., & Zhu, X. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.010 · Cited by 186
Boekhoorn, K., Terwel, D., Biemans, B. A. M., Borghgraef, P., Wiegert, O., Ramakers, G. J. A., de Vos, K., Krugers, H. J., Tomiyama, T., Mori, H., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.5425-05.2006 · Cited by 167
“…van Praag et al., 1999; Shors et al., 2002; Jin et al., 2004; Shors, 2004), particularly because disruption or overexpression of human protein tau affects the cell cycle, neuronal maturation, and axonal elongation (Takei et al., 2000; Dawson et al., 2001; Zhao et al., 2003; Andorfer et al., 2005).”
BackgroundTau isoform regulation is region‐ and cell‐specific in mouse brain
McMillan, P., Korvatska, E., Poorkaj, P., Evstafjeva, Z., Robinson, L., Greenup, L., Leverenz, J., Schellenberg, G. D., & D'Souza, I. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21867 · Cited by 179
“In this model, expression of the normal tau protein is driven by the MAPT promoter and regulatory sequences (Andorfer et al., 2003, 2005).”
BackgroundThe PI3K-Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events
Bhaskar, K., Miller, M., Chludzinski, A., Herrup, K., Zagorski, M., & Lamb, B. T. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-14 · Cited by 177
“Third, neuronal CCEs are observed in a variety of transgenic mouse models of AD [3, 8 ].”
BackgroundJohnson, A. (2018) · Springer Singapore · doi:10.1007/978-981-13-0508-5 · Cited by 175
“Like CELF1, hnRNP H regulates INSR splicing in the opposite direction compared to MBNL1/2 [97].”
Cell division in the CNS: Protective response or lethal event in post-mitotic neurons?
Yang, Y., & Herrup, K. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.10.002 · Cited by 157
“[108] Andorfer C, Acker CM, Kress Y et al.”
BackgroundA Decade of Tau Transgenic Animal Models and Beyond
Götz, J., Deters, N. A., Doldissen, A., Bokhari, L., Ke, Y. D., Wiesner, A., Schönrock, N., & Ittner, L. M. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00051.x · Cited by 180
“Furthermore, evidence for a role of cell cycle-regulated genes in neurodegeneration has been obtained in mice transgenic for wild-type human tau (3) and in tau-expressing human neuroblastoma cells (Hoerndli et al, unpublished).”
BackgroundThe sour side of neurodegenerative disorders: the effects of protein glycation
Miranda, H. V., & Outeiro, T. F. (2009) · The Journal of Pathology · doi:10.1002/path.2682 · Cited by 172
“Over-expression of tau protein (a microtubule-associated protein), hyperphosphorylation and mutations are known to contribute to its aggregation [60–62].”
BackgroundProteostasis of tau. Tau overexpression results in its secretion via membrane vesicles
Simón, D., García‐García, E., Royo, F., Falcón‐Pérez, J. M., & Ávila, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.11.022 · Cited by 166
Castillo‐Carranza, D. L., Gerson, J. E., Sengupta, U., Guerrero‐Munoz, M. J., Lasagna‐Reeves, C. A., & Kayed, R. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132477 · Cited by 190
“Additionally, in animal models, disease phenotypes are not associated with NFT levels [7–15], including in mice overexpressing human tau (Htau mice) [16, 17].”
The role of extracellular Tau in the spreading of neurofibrillary pathology
Medina, M., & Avila, J. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00113 · Cited by 161
“…et al., 2010), axonogenesis (DiTella et al., 1994; Klein et al., 2002; Belkadi and LoPresti, 2008), interactions with the plasma membrane (Brandt et al., 1995; Lee et al., 1998; Maas et al., 2000), signal transduction (Lee et al., 2004; Ittner et al., 2010) and cell cycle (Andorfer et al., 2005).”
BackgroundFactors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice
Gamache, J., Benzow, K. A., Forster, C. L., Kemper, L. J., Hlynialuk, C. J. W., Furrow, E., Ashe, K. H., & Koob, M. D. (2019) · Nature Communications · doi:10.1038/s41467-019-10428-1 · Cited by 174
Tissue-nonspecific Alkaline Phosphatase Promotes the Neurotoxicity Effect of Extracellular Tau
Díaz-Hernández, M., Gómez‐Ramos, A., Rubio, A., Gómez‐Villafuertes, R., Naranjo, J. R., Miras‐Portugal, M. T., & Ávila, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.145003 · Cited by 163
Nilson, A. N., English, K. C., Gerson, J. E., Whittle, T. B., Crain, C. N., Xue, J. J., Sengupta, U., Castillo‐Carranza, D. L., Zhang, W., Gupta, P. K., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160912 · Cited by 178
“Inflammation and cell death occur prior to, or independently, from the formation of NFTs in AD and in transgenic mouse models [9, 12, 13, 15, 31].”
BackgroundWhy Pleiotropic Interventions are Needed for Alzheimer's Disease
Frautschy, S. A., & Cole, G. M. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8137-1 · Cited by 152
“Our ongoing studies (unpublished) show that a cocktail containing both DHA and bioavailable curcumin can limit cognitive deficits and tau pathology in human tau mice beginning treatment at 14 months which is well after tau pathology and cognitive deficits had developed [190, 191].”
BackgroundKimura, T., Yamashita, S., Fukuda, T., Park, J., Murayama, M., Mizoroki, T., Yoshiike, Y., Sahara, N., & Takashima, A. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601917 · Cited by 144
“PHF1 immunoreactivity, however, differed between adult and aged mice.”
BackgroundInfluentialLysosomal Dysfunction Promotes Cleavage and Neurotoxicity of Tau In Vivo
Khurana, V., Elson‐Schwab, I., Fulga, T. A., Sharp, K. A., Loewen, C. A., Mulkearns-Hubert, E. E., Tyynelä, J., Scherzer, C. R., & Feany, M. Β. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001026 · Cited by 152
“We have previously shown that tau-induced cell cycle reentry mediates neuronal apoptosis in the fly tauopathy model [18], a result that has been corroborated in rodent models model of tauopathy [23,24].”
Lee, H., Casadesús, G., Zhu, X., Castellani, R. J., McShea, A., Perry, G. L., Petersen, R. B., Bajić, V., & Smith, M. A. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.10.013 · Cited by 136
“Interestingly, a recent transgenic mice study demonstrated that the overexpression of normal human tau protein induces neuronal apoptosis and cell cycle re-entry (Andorfer et al., 2005).”
BackgroundInfluentialThe Role of Telomerase Protein TERT in Alzheimer's Disease and in Tau-Related Pathology In Vitro
Spilsbury, A., Miwa, S., Attems, J., & Saretzki, G. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2925-14.2015 · Cited by 140
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
Maphis, N., Jiang, S., Xu, G., Kokiko-Cochran, O. N., Roy, S. M., Van Eldik, L. J., Watterson, D. M., Lamb, B. T., & Bhaskar, K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0221-y · Cited by 147
“Notably, original reports on hTau mice suggested formation of mature tangles and neurodegeneration by 20 months of age [45, 62, 63].”
Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity
d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062402 · Cited by 144
Self-citationTarget Identification for CNS Diseases by Transcriptional Profiling
Altar, C. A., Vawter, M. P., & Ginsberg, S. D. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.172 · Cited by 139
“…tangles: Histopathological and biochemical studies show that hippocampal CA1 pyramidal neurons of the AD brain bear intracellular NFTs, which have been modeled in mice that overexpress the human t protein (Ginsberg et al, 1999b; Trojanowski and Lee, 2005; Gotz, 2001; Andorfer et al, 2005).”
CSF biomarkers predict rate of cognitive decline in Alzheimer disease
Kester, M. I., van der Vlies, A. E., Blankenstein, M. A., Pijnenburg, Y. A. L., van Elk, E. J., Scheltens, P., & van der Flier, W. M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd8271 · Cited by 159
Repetitive mild traumatic brain injury augments tau pathology and glial activation in aged hTau mice
Ojo, J.-O., Mouzon, B., Greenberg, M. B., Bachmeier, C., Mullan, M., & Crawford, F. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182814cdf · Cited by 166
“This pathology is spatially distributed in relevant brain areas, such as the neocortex and hippocampus, with minimal brainstem and spinal cord involvement (30, 31).”
BackgroundSpires-Jones, T. L., de Calignon, A., Matsui, T., Zehr, C., Pitstick, R., Wu, H.-Y., Osetek, J. D., Jones, P. B., Bacskai, B. J., Feany, M. B., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3072-08.2008 · Cited by 137
The Basal Forebrain Cholinergic Projection System in Mice
Záborszky, L., van den Pol, A. N., & Gyengési, E. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-369497-3.10028-7 · Cited by 173
“Aged mice expressing nonmutant human tau in the absence of mouse tau (Htau mice) developed NFTs and extensive cell death in the piriform cortex and hippocampus (Andorfer et al., 2005).”
BackgroundThe synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 162
“Tau directly induces synaptic loss and dysfunction Tau can have toxic effects on the synapse resulting in density loss and synaptic dysfunction independent from Aβ [32].”
BackgroundCdk5: Multitasking between physiological and pathological conditions
Lopes, J. P., & Agostinho, P. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.03.006 · Cited by 134
“Cell cycle re-entry has been observed in different neurodegenerative conditions, such as AD, PD, ALS or stroke (Ahn et al., 2008; Andorfer et al., 2005; Hoglinger et al., 2007; Lopes et al., 2009c; Neve and McPhie, 2006; Nguyen et al., 2003; Rashidian et al., 2005; Wen et al., 2005).”
Tau Aggregation and Toxicity in a Cell Culture Model of Tauopathy
Bandyopadhyay, B., Li, G., Yin, H., & Kuret, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700192200 · Cited by 139
Therapeutic strategies for tau mediated neurodegeneration
Yoshiyama, Y., Lee, V. M. ‐., & Trojanowski, J. Q. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303144 · Cited by 137
New perspectives on the role of tau in Alzheimer's disease. Implications for therapy
Medina, M., & Ávila, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.013 · Cited by 123
“The first one uses the same 30mer peptide described above [102] in hTau/PS1 mice, which express all six wild-type isoforms of human tau on a mouse tau knockout background [34] plus human mutant (M146L) presenilin 1 (PS1) [105].”
Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 130
Tau as a Biomarker of Neurodegenerative Diseases
Schraen‐Maschke, S., Sergeant, N., Dhaenens, C., Bombois, S., Deramecourt, V., Caillet‐Boudin, M., Pasquier, F., Maurage, C., Sablonnière, B., Vanmechelen, E., et al. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.4.363 · Cited by 129
Tau‐targeted treatment strategies in Alzheimer's disease
Götz, J., Ittner, A., & Ittner, L. M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01713.x · Cited by 130
“Similar results were obtained by immunizing mice that express all six human tau isoforms on an MAPT-/- background, the htau model (Andorfer et al., 2005), together with M146L mutant PS1 (Boutajangout et al.”
ResultLessons from Tau-Deficient Mice
Ke, Y. D., Suchowerska, A. K., van der Hoven, J., Silva, D. M. D., Wu, C. W., van Eersel, J., Ittner, A., & Ittner, L. M. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/873270 · Cited by 142
“These aged mice are further characterized by neuronal loss together with ventricle enlargement and reduced cortical thickness [56].”
Background
Metadata
- Authors
- Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P.
- Affiliations
- Albert Einstein College of Medicine (US)
- Icahn School of Medicine at Mount Sinai (US)
- Nathan Kline Institute for Psychiatric Research (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2005-06-01
- Volume
- 25
- Issue
- 22
- Pages
- 5446-5454
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6725006
- OpenAlex
- W2016758992
- Cited by
- 511
- References
- 74
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 10 · 2023: 28 · 2022: 18 · 2021: 16 · 2020: 26 · 2019: 17 · 2018: 20 · 2017: 20 · 2016: 17 · 2015: 22 · 2014: 29 · 2013: 25 · 2012: 26
- FWCI
- 20.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (38623)
- National Institute on Aging (R37AG022102, AG022102, R01AG022102)
- National Institute of Mental Health (38623)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- tau protein, cell cycle re-entry, neuronal cell death, neurofibrillary tangles, tauopathy, Alzheimer's disease, transgenic mice, neurodegeneration, DNA synthesis, tau filaments
- MeSH terms
- Aging, Animals, Brain, Bromodeoxyuridine, Cell Cycle, Humans, Mice, Transgenic, Nerve Degeneration, Nerve Tissue Proteins, Neurons, Neurofibrillary Tangles, tau Proteins, Cell Death, Protein Isoforms, Mice, DNA Fragmentation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review